Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase | 0.8199 | 0 | 0.5 |
Chlamydia trachomatis | bifunctional 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase/dihydropteroate synthase | 0.8199 | 0 | 0.5 |
Toxoplasma gondii | dihydropteroate synthase | 0.8199 | 0 | 0.5 |
Mycobacterium ulcerans | 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase | 3.3492 | 1 | 0.5 |
Plasmodium vivax | hydroxymethylpterin pyrophosphokinase-dihydropteroate synthetase, putative | 0.8199 | 0 | 0.5 |
Mycobacterium tuberculosis | 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase FolK (7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase) ( | 2.5796 | 0.6957 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IZ (functional) | = 26 mm | Antifungal activity against Candida albicans MTCC 3017 at MIC after 48 hrs by disc diffusion method | ChEMBL. | No reference |
IZ (functional) | = 26 mm | Antibacterial activity against Escherichia coli MTCC 2622 at MIC after overnight incubation by disc diffusion method | ChEMBL. | No reference |
MIC (functional) | = 8 ug ml-1 | Antifungal activity against Candida albicans MTCC 3017 at 37 degC after 48 hrs by microbroth dilution technique | ChEMBL. | No reference |
MIC (functional) | = 16 ug ml-1 | Antibacterial activity against Escherichia coli MTCC 2622 after 24 hrs by two-fold dilution method | ChEMBL. | No reference |
MIC (functional) | > 200 ug ml-1 | Antibacterial activity against Escherichia coli ATCC 25922 after 12 hrs by broth-dilution method | ChEMBL. | 27080179 |
MIC (functional) | > 200 ug ml-1 | Antifungal activity against Saccharomyces cerevisiae ATCC 9763 after 12 hrs by broth-dilution method | ChEMBL. | 27080179 |
MIC (functional) | > 200 ug ml-1 | Antifungal activity against Candida albicans ATCC 10231 after 12 hrs by broth-dilution method | ChEMBL. | 27080179 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.